What is the recommended treatment for skin infections caused by Streptococcus (Strep) anginosus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Skin Infections Caused by Streptococcus anginosus

For skin infections caused by Streptococcus anginosus, penicillin is the drug of choice, with alternatives including clindamycin or a first-generation cephalosporin depending on infection severity and patient factors. 1

First-Line Treatment Options

  • Mild infections: Oral penicillin or amoxicillin is the preferred treatment for uncomplicated skin infections caused by Streptococcus anginosus, which remains highly susceptible to penicillins 1
  • Moderate to severe infections: For more serious infections, parenteral therapy with penicillin G or ampicillin is recommended 1, 2
  • Amoxicillin is FDA-approved for skin and skin structure infections due to susceptible strains of Streptococcus species (α- and β-hemolytic isolates) 3

Alternative Treatments

  • For penicillin-allergic patients: Clindamycin is an excellent alternative with good activity against S. anginosus group organisms 1, 4
  • First-generation cephalosporins (cefazolin, cephalexin) can be used for non-severe reactions to penicillin, but are contraindicated in patients with immediate hypersensitivity reactions 5, 2
  • Vancomycin should be reserved for patients with severe penicillin allergy or treatment failures 2

Treatment Duration

  • Treatment should continue for 7-14 days based on clinical response 2
  • For any infection caused by streptococcal species, a minimum of 10 days of treatment is recommended to prevent complications such as acute rheumatic fever 3

Special Considerations

  • S. anginosus group organisms often cause polymicrobial infections (70% of cases), frequently with gram-negative anaerobes and Enterobacteriaceae 6
  • For polymicrobial infections involving S. anginosus, broader coverage may be necessary with agents such as ampicillin-sulbactam or piperacillin-tazobactam 2
  • Despite their ability to form abscesses, skin infections with S. anginosus generally have a low mortality rate (3%) 6

Management of Abscesses

  • Any abscess formation requires incision and drainage as the primary intervention 2
  • For abscesses with systemic signs of infection, antimicrobial therapy should accompany drainage 2
  • Cultures from abscesses should be obtained to guide antimicrobial therapy, especially in patients with severe infection or those not responding to initial treatment 2

Monitoring and Follow-up

  • Patients should be reevaluated within 24-48 hours to verify clinical response 2
  • If there is progression despite appropriate antibiotics, consider:
    • Resistant organisms (though uncommon with S. anginosus) 1, 4
    • Deeper or more serious infection requiring surgical intervention 2
    • Possible polymicrobial infection requiring broader coverage 6

Important Caveats

  • Although intermediate resistance to penicillin has been reported in some S. anginosus isolates (5.6%), the vast majority remain highly susceptible 4
  • Resistance to erythromycin (17.1%) and clindamycin (16.6%) has been reported, so susceptibility testing is valuable when available 4
  • S. anginosus bacteremia can rarely be associated with deeper infections including endocarditis or underlying conditions such as colon cancer, requiring thorough evaluation in bacteremic patients 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Five-year analysis of antimicrobial susceptibility of the Streptococcus milleri group.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1999

Research

Streptococcus anginosus Group Bacterial Infections.

The American journal of the medical sciences, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.